. Overexpression of VEGF-C attenuates chronic high salt intake-induced left ventricular maladaptive remodeling in spontaneously hypertensive rats.
A GROWING BODY OF EVIDENCE has shown that high salt (HS) intake is an important environmental factor involved in the aggravation of hypertension-related cardiovascular disease (1, 14, 34) . The results from recent clinical and experimental studies indicate that the adverse effect of HS intake on target organ damage could be independent of its influence on blood pressure (BP) (8, 12, 35, 48) . Macrophage infiltration in hypertensive target organs has been demonstrated in animal models (5, 16, 43) , and an increasing number of macrophage infiltration is associated with an exacerbation of the damage to target organs (9, 20, 41) . Our recent work also demonstrated that HS intake-induced pro-inflammatory activation of monocytes is associated with end organ inflammation in humans (58) . However, the detailed mechanism of macrophage-induced target organ damage is still unclear.
Recent studies have provided new insights into macrophages and lymphangiogenesis in the contex of interstitial Na ϩ and BP homeostasis. Elevated Na ϩ ϩ K ϩ -to-water ratio skin paralleled by increased glycosaminoglycans content and sulfation is not only a feature of osmotically inactive Na ϩ storage but also leads to hypertonicity and osmotic stress in the skin interstitium (31) . In response to the osmotic stress associated with skin Na ϩ storage, tonicity-responsive enhancer binding protein (TonEBP) is upregulated in the interstitial macrophages. TonEBP binds to the promoter region of the gene encoding for vascular endothelial growth factor-C (VEGF-C) and causes VEGF-C secretion. This secretion results in increased density of the lymph capillary network via the VEGF-C/vascular endothelial growth factor receptor 3 (VEGFR-3) signaling pathway (47) . The lymphatic vasculature plays an important role in fluid homeostasis and immune regulation (38) . Many studies have shown that cardiac lymphatic obstruction leads to myocardial edema, lymphangiectasis, and cardiac fibrosis and, ultimately, aggravates heart failure (7, 21, 24, 26, 29) . Further studies have demonstrated that a blockade of this macrophagedriven regulatory response not only increases BP levels in the presence of salt-sensitive hypertension (31) but also converts the organism from a salt-resistant to a salt-sensitive state (30) . Thus far, the impact of HS intake on the cardiac lymphatic system and the role of VEGF-C in modulating HS intakeinduced ventricular dysfunction have not been addressed. Therefore, the present study was designed to 1) investigate the effect of HS intake on cardiac macrophage infiltration and lymphangiogenesis in spontaneously hypertensive rats (SHR), and 2) investigate the role of VEGF-C/VEGFR-3 signaling in the modulation of left ventricular (LV) remodeling induced by chronic HS intake in SHR.
METHODS

Retrovirus preparation. Three retrovirus vectors, ⌬N⌬C/VEGF-C/
Cys152Ser retrovirus vector (used for overexpressing VEGF-C), VEGFR-3-Rg retrovirus vector (used for trapping of bioactive VEGF-C), and control pLPCX retrovirus vector, were produced for the retrovirus study below. Detailed methods for retrovirus preparation are presented in supporting information.
Animals. All animals were obtained from the Laboratory Animal Center of the Academy of Military Medical Sciences (Beijing, China) and received humane care in compliance with the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, revised 1996). The study protocol was approved by the institutional review board. We first used our previous samples to investigate lymphangiogenesis and macrophage infiltration in HS-diet-fed SHR and Wistar Kyoto rats (WKY) (10) , in which study the WKY and SHR were fed a 0.5%, 4.0%, and 8.0% NaCl diet for 12 wk. Then, we conducted a VEGF-C-targeted intervention study. Briefly, 8-wk-old male SHR were given either a 0.5% [low salt (LS); n ϭ 10] or an 8.0% (HS; n ϭ 40) NaCl diet for 12 wk. WKY fed on a LS diet were used as the negative controls (n ϭ 10). The HS-fed SHR were then divided into four groups: HS (n ϭ 10), HS ϩ RetroVEGF-C (HS ϩ VC; n ϭ 10), HS ϩ RetroVEGR-3-Rg (HS ϩ VRg; n ϭ 10), and HS ϩ RetroCtr (HS ϩ Ctr; n ϭ 10) and were administered different types of retroviral vectors in the following experiments. All rats were permitted free access to chow and tap water. The systolic blood pressure (SBP) was dynamically measured in conscious rats using the tail-cuff method, as previously described (10) . At the end of follow-ups (12 wk after dietary intervention), the rats were subject to echocardiographic and LV hemodynamic analyses. Then, the heart was removed and prepared for histology and other assays. LV mass (LVM) was measured after the aorta, the atrium, and the free wall of right ventricle were removed, and the LVM indexes (LVMI) were calculated as the ratio of LVM to tibia length. The LV apex and basal part were removed, and the remaining tissue was divided into three parts for RNA extraction, pathological analysis, and protein assays, respectively.
Intravenous injection of retroviral vectors. From week 9 of HS loading, HS ϩ VC, HS ϩ VRg, and HS ϩ Ctr groups were administered with corresponding retrovirus vectors for the remaining 4 wk of the 12-wk dietary intervention. The SHR was placed in a constrictive rat cage to expose its tail. The animals were administered 0.5 ml of retrovirus vector via tail vein and injected in a 1-wk interval for four times in total.
Echocardiography. At the end of the 12-wk dietary intervention, all animals were anesthetized (pentobarbital sodium, 40 mg/kg, ip) and examined noninvasively using an echocardiographic system equipped with a 12.0-MHz transducer (Vivid7, GE Medical System, Horton, Norway). Two-dimensional guided M-mode echocardiography was performed to evaluate the LV end-diastolic diameter (LVEDD), the LV end-systolic diameter (LVESD), the LV end-diastolic volume (LVEDV), and the LV end-systolic volume (LVESV). As previously described (44) , the LV fractional shortening (LVFS) and LV ejection fraction (LVEF) were calculated as LVFS (%) ϭ [(LVEDD Ϫ LVESD)/LVEDD] ϫ 100, and LVEF (%) ϭ [(LVEDV Ϫ LVESV)/ LVEDV] ϫ 100, respectively. The measurements from at least three consecutive cycles were averaged. A sonographer, blind to the treatment groups, collected all the measurements.
Invasive hemodynamic measurements. After echocardiographic analysis, all rats were anesthetized (pentobarbital sodium, 60 mg/kg, ip) for invasive LV hemodynamic measurements, as previous described (4) . Briefly, a 2-Fr micro-tip pressure catheter (model SPR-320; Millar Instruments, Houston, TX) was advanced into the LV through the right carotid artery, and the LV function was continuously recorded using a physiological data acquisition system (MP150, Biopac Systems, Goleta, CA). The calculated hemodynamic parameters were as follows: the LV end-diastolic pressure (LVEDP), the maximal slope of systolic pressure increment (ϩdP/dt max), and the diastolic pressure decrement (ϪdP/dt min).
Histology. After in vivo hemodynamic measurements were collected, all rats were then killed by pentobarbital sodium overdose (100 mg/kg, ip). Heart samples used for histological evaluation were incubated in 4% formalin, embedded in paraffin, and sectioned into 5-m slices for staining. Picro-Sirius red staining was performed to determine the collagen deposition in the heart. The images were visualized on a polarizing microscope (E600POL, Nikon, Tokyo, Japan) equipped with a circular polarizer (Kenko, Tokyo, Japan), as described previously in our laboratory's prior work (57) , and digitalized with a color CCD (Pro 150ES, Pixera, Los Gatos, CA). At ϫ100 magnification, 10 representative fields per LV cross section were imaged. PSR-stained interstitial and perivascular collagen fibers were highlighted, giving a pixel count for the amount of collagen represented in each field. We then calculated the average collagen volume fraction (CVF) and the ratio of perivascular collagen area to lumen area (PVCA/LA) for further analysis. To determine the mean cardiomyocyte cross-sectional area (CSA), we stained LV sections with tetramethylrhodamine isothiocyanate (TRITC)-labeled wheat germ agglutinin (WGA; 1:100 dilution, Invitrogen, Grand Island, NY). The nuclei were then counterstained nuclei with 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA). The sections were examined with a fluorescence microscope (80i, Nikon, Tokyo, Japan), as previously described (27, 57) . Ten representative fields per LV cross section at ϫ200 magnification were imaged, 50 cells in each field were randomly selected, and the mean cardiomyocyte CSA were calculated. We took the average CSA of the 10 fields for analysis.
For determination of lymphangiogenesis and cardiac macrophage density, immunohistochemical staining was performed. Slides were dewaxed, and unspecific protein binding sites were blocked with goat serum for 20 min at room temperature. The sections were then incubated with specific primary antibodies against POD (Cell sciences, Canton, MA; 1:200 in dilution), Lyve-1(Abcam, San Francisco, CA; 1:100 in dilution), and CD68 (AbD Serotec, Raleigh, NC; 1:100 in dilution) in blocking solution for 16 h at 4°C. Afterward, the sections were washed three times in PBS and then incubated with Polink-2 plus Polymer HRP Detection System (Golden Bridge International), according to the manufacturer's instructions. The nuclei were counterstained with hematoxylin. All image analyses were performed in a blind fashion using Image Pro Plus (version 4.5, Media Cybernatics, Silver Spring, MD).
Lyve and POD-positive lymphatic vessels were calculated as selected 10 representative fields at ϫ200 magnification, and the total lymphatic vessels in epicardium, midcardium, and endocardium were counted for analysis. The lymphatic vessel areas were calculated as total lymphatic vessel areas devided by total lymphatic vessel numbers. To determine macrophage density, we randomly selected 10 representative fields at ϫ400 magnification in epicardium, midcardium, and endocardium, and calculated the average numbers of the CD68-positive cells for analysis.
In the VEGF-C-targeted intervention study, we selected 10 representative fields per LV cross section at ϫ200 magnification and calculated the average numbers of the CD68-positive cells for analysis. And the number of POD-positive lymphatic vessels were calculated as the total values of 10 representative fields per LV cross section at ϫ200 magnification.
Quantitative real-time RT-PCR. Heart tissue (ϳ100 mg) was homogenized in liquid nitrogen with a mortar. RNA was extracted using Trizol Reagent (Takara Bio, Kyoto, Japan), according to the manufacturer's recommendations. Total RNA (2 g) was reverse-transcribed into the cDNA using a reverse transcription assay (Promega, Madison, WI) in 25 l of reaction volume, according to the manufacturer's instructions. Real-time PCR was performed using the ABI Prism 7300 sequence detection system (Applied Biosystems, Foster City, CA). The RNA expression levels were then determined for ␤-actin, Prospero homeobox 1(Prox-1), lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1), podoplanin (POD), tonicity-responsive enhancer binding protein (TonEBP), and vascular endothelial growth factor C (VEGF-C) using the SYBR Green PCR master mix (Roche Diagnostics, Indianapolis, IN) in real-time PCR. All primers used in the real-time PCR are shown in Table 1 .
Western blotting. Heart samples were thawed and homogenized in 500 l of lysis buffer containing protease inhibitors and 1% Triton X-100. After determination of the protein concentration, 50 g of supernatants were electrophoresed through 10% SDS-PAGE in Trisglycine buffer and transferred to a polyvinylidene fluoride membrane. The nonspecific binding sites were blocked with 5% nonfat skim milk in PBS containing 0.1% Tween-20. The membranes were then incubated overnight at 4°C with primary antibodies against VEGF-C (Abcam, Cambridge, MA; 1:1,000 in dilution), TonEBP (Abcam; 1:1,000 in dilution), Prox-1 (Abcam; 1:1,000 in dilution), VEGFR-3 (Abbiotec, San Diego, CA; 1:1,000 in dilution), and GAPDH (Abcam; 1:2,000 in dilution). After being washed, the binding of the primary antibody was detected with the use of peroxidase-conjugated secondary antibodies for 40 min at 37°C. The relevant protein signal was amplified with Western chemiluminescent horseradish peroxidase (HRP) substrate (Millipore, Billerica, MA) and detected using a Chemi DOC XRSϩ Imaging System (Bio-Rad, Hercules, CA). Densitometric analyses were performed with Image J software (NIH, Bethesda, MD).
Statistical analysis. Data are presented as means Ϯ SE. SBPs were compared among the groups using ANOVA for repeated measures followed by a post hoc analysis with the Bonferroni test. Other results were analyzed using one-way ANOVA followed by the Bonferroni test for multiple comparisons. Relationships between macrophage/ lymphatic vessel density and pathological measures were evaluated with Pearson correlation (data passed normality test) or Spearman rank correlation (data failed normality test). A two-tailed P Ͻ 0.05 was considered statistically significant. All data were analyzed using GraphPad Prism 5.0 (GraphPad, San Diego, CA).
RESULTS
Effects of dietary intervention with different NaCl content (0.5, 4.0, and 8.0%) on BP level, myocardial macrophage infiltration, and lymphangiogenesis in WKY and SHR.
We first evaluated the dose-dependent effects of diets containing different NaCl content on BP level, cardiac macrophage infiltration, and lymphangiogenesis. As shown in supplemental Table  1 (available online) , although a BP-elevation effect was observed in WKY and SHR fed by high NaCl diets (4.0% and 8.0%), there was no statistical differences in BP levels between rats fed by 4.0% and 8.0% diets, both in WKY and in SHR. In addition, we found that the 8.0% diet significantly increased macrophage infiltration compared with the 0.5% and 4.0% NaCl diets in the SHR groups. However, no significant differences were found among the WKY groups (Fig. 1, A, D, and E) . To examine the TonEBP/VEGF-C-induced lymphangiogenesis, the expression of TonEBP, VEGF-C, Lyve-1, POD, and Prox-1 was measured. As expected, the mRNA levels of these factors were all significantly increased compared with the 0.5% and 4% NaCl diets in SHR groups, whereas no significant differences were found among the WKY groups (Fig. 2, A-E) .
Histological examination demonstrated that the number of Lyve-1-and POD-positive lymphatic vessels was significantly increased and presented apparent lymphangiectasis in the 8% NaCl diet SHR group compared with the 0.5% NaCl SHR group (Fig. 1, B , C, and F-M). These results indicate that HS (4.0% and 8.0% NaCl) diet could dose-dependently increase myocardial macrophage infiltration and lymphangiogenesis in SHR. Moreover, this effect is not entirely dependent on BP level, since we did not observe BP changes in rats consuming 4.0% and 8.0% NaCl diets. Therefore, in the following experiments, we conducted VEGF-C targeted interventions in SHR fed with 0.5% and 8.0% NaCl diets, using a protocol based on our laboratory's previous work (10) .
Changes of LV and body mass, and BP level in VEGF-C targeted intervention study. Table 2 shows that body weight was not significantly different among the six groups, although the HS groups have a lower weight than the WKY and LS groups. However, the LVM in the HS groups was significantly higher compared with the WKY and LS groups. Additionally, the LV mass index (LVM/tibial length, mg/mm) was significantly increased in the HS groups compared with the WKY and LS groups, whereas no significant differences were observed across the HS groups. 
Prox-1, prospero homeobox 1; Lyve-1, lymphatic vessel endothelial hyaluronan receptor 1; POD, podoplanin; TonEBP, tonicity-responsive enhancer binding protein; VEGF-C, vascular endothelial growth factor C; RetroVEGF-C, ⌬N⌬C/VEGF-C/Cys152Ser retrovirus vector; RetroVEGR-3-Rg, VEGFR-3-Rg retrovirus vector; RetroCtr, control pLPCX retrovirus vector.
The BP levels gradually increased in the SHR groups from baseline over the 12 wk. Compared with the WKY group, the BPs of the SHR groups were significantly higher at all time points. At the end of the 12-wk dietary intervention, the BP of the HS ϩ VC group was significantly lower, whereas the HS ϩ VRg group was significantly increased compared with the HS and HS ϩ Ctr groups (Table 2) .
Echocardiographic parameters and invasive LV hemodynamics. The echocardiographic analysis showed that the LV enlargement was more severe in the HS groups compared with the LS group (Fig. 3, A-C) . RetroVEGF-C treatment significantly ameliorated LV enlargement compared with the HS ϩ VRg group (reduction of LVEDD and LVEDV by 22.2% and 40.7%, respectively; all P＜0.05). The LVEF and LVFS were both markedly improved in the HS ϩ VC group compared with the HS ϩ VRg group (increase of LVEF and LVFS by 12.5% and 28.7%, respectively; all P＜0.05) (Fig. 3, A-E) .
The LV invasive hemodynamic analysis revealed that, compared with the HS ϩ VRg group, overexpression of VEGF-C significantly reduced LVEDP (4.073 Ϯ 1.144 vs. 12.84 Ϯ (Fig. 3F ). As shown in Fig. 3G , LV contractility (ϩdP/dt max ) was increased significantly in the HS and HS ϩ Ctr groups compared with the LS and WKY groups. Across the HS groups, LV contractility increased significantly in the RetroVEGF-C treatment group and deteriorated severely in the RetroVEGFR-3-Rg group (6,706 Ϯ 121 vs. 5,476 Ϯ 137 mmHg/s; P＜0.0001). Moreover, active diastolic (ϪdP/dt min ) function in the HS ϩ VRg group was exacerbated compared with the other HS groups (P＜0.05) but partially improved in the HS ϩ VC group [no significant differences were found (Fig. 3H)] .
Myocardial expression of lymphatic markers, TonEBP, and VEGF-C. The real-time RT-PCR and Western blot analysis demonstrated that the TonEBP expression was significantly upregulated in the HS groups compared with the WKY and LS groups (Fig. 4, A, J, and K) . No significant differences were found across the HS groups. The mRNA expression of the lymphatic markers, i.e., Prox-1, Lyve-1, and POD, incresed statistically in the HS groups compared with the WKY and LS groups. Compared with the HS group, the mRNA levels of Prox-1, Lyve-1, and POD were increased by 38.8, 35.5, and 34.7%, respectively, in the HS ϩ VC group (P Ͻ 0.05).
In contrast, these markers were downregulated in the HS ϩ VRg group, indicating a diminished response to VEGF-Cinduced lymphangiogenesis. The VEGF-C mRNA expression was significantly higher in the HS groups compared with the WKY and LS groups, and higher in the HS ϩ VC group compared with the other HS groups (P＜0.05) (Fig. 4, A-E) . The Western blot analysis of Prox1 further confirmed unregulation of lymphatic marker in the HS ϩ VC group and downregulation in the HS ϩ VRg group (Fig. 4, F and G) .
Myocardial expression of RetroVEGF-C and RetroVEGFR-3-Rg in HS intake SHR.
We used Western blot analysis to test the expression of RetroVEGF-C and RetroVEGR-3-Rg in the HS groups and found that both were successfully expressed (Fig. 4, H and I) .
Pathological findings and correlation analysis. As illustrated in Fig. 5 , collagen deposition revealed by the picro-sirius red staining showed that HS intake increased collagen deposition both in the perivascular region (Fig. 5, A and D) and the myocardial interstitium (Fig. 5, B and E) . Moreover, the collagen deposition was significantly increased in the HS ϩ VRg group (increased by 30% in perivascular region and by 70% in myocardial interstitium; P＜0.05, compared with HS group); however, they were reduced by ϳ50% in the HS ϩ VC group compared with the HS and HS ϩ Ctr groups (P＜0.05). WGA staining revealed that the myocardial CSA was significantly increased in the HS groups compared with the LS and WKY groups. Among the HS groups, the mean CSA of cardiomyocytes increased by 45% in the HS ϩ VRg group and decreased by 44% in the HS ϩ VC group compared with the HS group (Fig. 5, C and F) . In addition, HS intake significantly increased macrophage (CD68 ϩ cells) density in the myocardial interstitium compared with the WKY and LS groups. The RetroVEGFR-3-Rg treatment group had increased macrophage density, whereas RetroVEGF-C treatment showed a marked decrease in macrophage infiltration compared with the other HS groups (Fig. 6, A and B) .
To investigate lymphangiogenesis in the myocardial interstitium, we performed immunohistochemical staining of the lymphatic vessels with a POD-specific antibody and revealed that the HS intake resulted in a marked increase in the density of lymphatic vessels in the heart tissues of SHR. Moreover, compared with the HS group, RetroVEGF-C treatment promoted lymphangiogenesis by a 60% increase (40 Ϯ 3 per 10 fields vs. 25 Ϯ 2 per 10 fields; P＜0.05), whereas RetroVEGR-3-Rg treatment inhibited lymphangiogenesis 40% (15 Ϯ 1 per 10 fields vs. 25 Ϯ 2 per 10 fields; P＜0.05) in the HS groups (Fig. 6, C and D) .
Correlation analyses were then carried out to evaluate the association among macrophage/lymphatic vessel density, myocardial fibrosis/hypertrophy, and BP levels in SHR. Because pathological evaluations were not performed in all killed SHR, only samples that simultaneously performed CD68 and POD immunological staining (n ϭ 3-4 each group) were pooled for analysis. The results showed that cardiac CD68 ϩ cells were positively correlated with BP level (Fig. 7A) , collagen deposition (Fig. 7, B and C) , cardiomyocyte hypertrophy (Fig. 7D) , and heart weight ( Fig. 7, E and F) , whereas there were no correlations between PODϩ lymphatic vessel density and these pathological measurements (Fig. 7, G-K) . Moreover, there was no statistical correlation between PODϩ vessel density and macrophage density (Fig. 7G) . These results indicate that the number of cardiac macrophage is quantitatively correlated with pathological LV remodeling, which is partially dependent on BP level. Interestingly, when only the data from SHR fed with HS diet were enrolled for analysis (Fig. 7, L-O) , lymphatic vessel density was negatively correlated with macrophage infiltration and collagen deposition, indicating a protective effect of cardiac lymphangiogenesis on LV remodeling. Moreover, as shown in Fig. 7M , lymphatic density was also negatively correlated with BP level, supporting a BP-buffering effect of lymphangiogenesis on HS intake-induced BP elevation, as described previously (31) .
DISCUSSION
The present study demonstrated the following: 1) chronic HS intake could dose-dependently increase cardiac macrophage and lymphatic vessel density in SHR, and this effect is not entirely dependent on change in BP level; 2) systemic overexpression of VEGF-C enhances myocardial interstitium lymphangiogenesis and attenuates HS intake accelerated progression of LV remodeling, reduces macrophage density, and ameliorates myocardial collagen deposition and cardiomyocyte hypertrophy in HS-diet-fed SHR; 3) systemic blockade of endogenous VEGF-C leads to exacerbation of hypertensive LV remodeling progression induced by HS intake; 4) both BPdependent and BP-independent mechanisms are involved in the cardiac-protective effect conferred by systemic VEGF-C overexpression in SHR fed by HS diet.
The BP of SHR begins to increase at an age of 8 wk; at 15-20 wk, it then develops to LV hypertrophy, and at 52-90 wk, cardiac dysfunction occurs (40) . Applying different concentrations of salt loading is a traditional method to promote the process of hypertension and its related target organ damage Fig. 4 . The expression of VEGF-C, VEGFR-3, TonEBP, and lymphatic markers in different groups after a 12-wk HS loading period. A-E: the statistical comparisons of mRNA expression levels in the heart tissues by real-time RT-PCR analysis. F and G: the Western blot analysis of cardiac Prox-1 levels. H: the Western blot analysis of VEGF-C, ⌬N/⌬C/VEGF-C/Cys152Ser expression in the heart tissues. I: the Western blot analysis of VEGFR-3 andVEGFR-3-Rg in the heart tissues. J and K: the representative Western blot images of TonEBP in LS and HS groups. Values displayed are means Ϯ SE (n ϭ 5 per group). *Significant difference vs. WKY group (P Ͻ 0.05). #Significant difference vs. LS group (P Ͻ 0.05). †Significant difference vs. HS group (P Ͻ 0.05). ‡Significant difference vs. HSϩ RetroVEGF-C (VC) group (P Ͻ 0.05). §Significant difference vs. HSϩ RetroVEGR-3-Rg (VRg) group (P Ͻ 0.05). (15, 33, 55) . Long-term HS intake can increase the expression of transforming growth factor ␤ and activate the renninangiotensin-aldosterone system, which promotes myocardial fibrosis and cardiac dysfunction (28, 49) . In our previous study, we found that 8 -12 wk after an 8% salt diet is initiated in SHR is the key time frame in which a transition from compensated to decompensated LV hypertrophy occurs (10) . Here, we used the 8% HS intake for 12 wk and found that the BP increased significantly accompanied by the deterioration of myocardial fibrosis and LV function, although in a hyperkinetic state, as in our previous study.
VEGFR-3 is expressed virtually exclusively in lymphatic endothelium and serves as a useful marker for lymphatic endothelial cells (17, 32) . VEGF-C, a known ligand for VEGFR-3, is a member of the vascular endothelial growth factor (VEGF)/platelet-derived growth factor (PDGF) family and can bind to VEGFR-3 to regulate lymphangiogenesis (2, 50) . It can also bind to VEGFR-2 to induce angiogenesis in some special circumstances (3, 39, 51) . VEGF-C is progressively processed during biosynthesis to remove the NH 2 -and COOH-terminal ends of the protein, leaving the central VEGF homology domain (VHD) (18, 45) . This processing progressively increases the affinity of VEGF-C for VEGFR-3. Recently, Kirkin et al. (19) created a recombinant rat VEGF-C protein that can inhibit its ability to activate VEGFR-2 by mutation of Cys 152 to Ser. Therefore, ⌬N⌬C/VEGF-C/ Cys152Ser is a useful tool for regulating lymphangiogenesis by its specific binding to VEGFR-3 (22) . To inhibit VEGFR-3 signaling pathway, Krishnan and coworkers used a rat VEGFR-3 and IgG2a heavy chain to reconstruct a fusion protein (VEGFR-3-Rg) that can specifically bind to VEGF-C and inhibit its role in regulating lymphangiogenesis (22) . Thus the application of ⌬N⌬C/VEGF-C/Cys152Ser and VEGFR-3-Rg can bilaterally modulate the VEGF-C signaling pathway.
An earlier study has demonstrated that long-term HS intake can cause hypertonicity and osmotic stress in the skin interstitium (31) . As a response to hypertonicity and osmotic stress, macrophages activate TonEBP to induce a local regulatory cascade to maintain homeostasis of the internal environment in the subcutaneous interstitium. TonEBP binds to the promoter region of VEGF-C and causes VEGF-C secretion, which actively controls the internal environment of the skin interstitium (47) . VEGF-C can bind to VEGFR-3 and induce lymphangiogenesis. Furthermore, the fully processed form of VEGF-C can activate VEGFR-2 to induce endothelial nitric oxide synthase (eNOS) expression (23) and angiogenesis (3, 39, 51) . As a buffering system, this mechanism dynamically regulates extracellular volume and BP homeostasis (31) . A blockade of this buffering system not only worsens hypertension in states of salt-sensitive hypertension (31) but also converts the organism from a salt-resistant state to a salt-sensitive state (30) . Moreover, this buffering system may be a compensatory mechanism of the body to HS and hypertension. Long-term HS loading and hypertension will ultimately induce the buffering system to decompensation, leading to severe hypertension and cardiac dysfunction. In the present work, we observed that HS intake for 12 wk in SHR elicited severe macrophage infiltration accompanied by myocardial interstitial lymphangiogenesis, which indicated that a similar mechanism may exist in the hearts of SHR.
The lymphatic vasculature is essential in the transport of tissue fluid, extravasated plasma proteins, and immune cells back to the blood circulation, and plays an important role in fluid homeostasis and immune regulation (38) . Evidence has shown that acute cardiac lymphatic obstruction leads to myocardial edema and local lymphangiectasis (7) , and contributes to cardiac systolic and diastolic dysfunction (29) . Chronic lymphatic obstruction leads to perivascular and interstitial fibrosis, causes cardiac structural and functional disorder, and ultimately leads to heart failure (21, 24, 26) . Thus the lymphatic vessels may play a protective role against HS challengeinduced LV remodeling, which seems to be a buffering mechanism, and long-term HS intake may lead to this mechanism decompensation and will cause severe LV remodeling. Using retrovirus capable of expressing functionally active VEGF-C may restore this buffering mechanism. In the present study, we used RetroVEGF-C, which can specifically activate VEGFR-3, and RetroVEGFR-3-Rg, which can inhibit VEGF-C binding to VEGFR-3, to bilaterally regulate the VEGF-C signaling pathway. The results demonstrated that the RetroVEGF-C treatment significantly increased myocardial interstitial lymphangiogenesis, preserved cardiac function, and ameliorated myocardial fibrosis and cardiomyocyte hypertrophy in the HS-diet-challenged SHR. In contrast, the RetroVEGFR-3-Rg treatment group presented the opposite effect.
Monocyte/macrophage infiltration is quantitatively associated with hypertensive end organ injury (13, 36) . In our recent work (58), we demonstrated that a 7-day HS intake could induce the expansion of CD14 ϩϩ CD16 ϩ monocyte pool in humans, a subset superior for endothelial adhesiveness, angiogenesis, and reactive oxygen species production (6, 52, 56) . In addition, the expansion of this subset independently predicts adverse cardiovascular events in patients with coronary heart disease (42) . Moreover, we showed that HS intake-induced CD14 ϩϩ CD16 ϩ monocytosis is associated with HS-induced end organ inflammation, which is independent of BP level (58) . Although recent studies demonstrated that tissue-resident macrophages are established before birth and maintain themselves subsequently during adulthood independent of replenishment from circulating monocyte input in steady state (11, 54) , during inflammation and disturbed homeostasis, such as ischemia or chronic HS intake, circulating monocytes have an important impact on the cardiac macrophage expansion (37, 46) . Because the cardiac lymphatic system provides an exit route for extravasated monocytes/macrophages (25) , dysfunction or destruction of cardiac lymphatic system would lead to delayed resolution of inflammation and monocytes/macrophages retention, as shown in our previous work (57) . Thus it is conceivable that enhanced cardiac lymphangiogenesis by upregulation of VEGF-C could facilitate cardiac macrophage clearance, whereas diminished lymphangiogenesis induced by "trapping" of VEGF-C could contribute to defect in macrophage exit.
Several study limitations should be acknowledged in this work. First, the retrovirus vector is not heart tissue specific. Systemic administration of retrovirus vector to the SHR will undoubtably contribute to extracardiac expression, which may involved in the BP regulatory effect by these vectors. Second, quantitative analysis of colocalization of TonEBP, VEGF-C, and macrophages in the heart may better elucidate the relationship between macrophage infiltration, VEGF-C expression, and lymphangiogenic response during HS challenge. Third, although we have demonstrated the in vitro activity of retrovirus vectors in our recent work (53) , the in vivo activity of these two vectors should be better demon- strated by evaluating VEGF-C/VEGFR-3 downstream signaling in the heart and extracardiac organs/tissues. And last, the potential impact of local macrophage proliferation and the relative contribution of heterogeneity of monocyte/ macrophage pool should be addressed in this model to dissect the exact mechanism by which increased macrophage density contributes to deterioration of LV remodeling during HS intake.
In conclusion, the present study demonstrates that chronic retrovirus-mediated systemic overexpression of VEGF-C could attenuate HS intake-induced LV maladaptive remodeling, whereas systemic blocking of VEGF-C contributes to worsening of LV function, which involves BP-dependent and -independent mechanisms. Our findings highlight that VEGF-C/ VEGFR-3 is a promising therapeutic target to attenuate hypertensive LV remodeling and end organ injuries that are aggravated by HS intake.
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